Speakers 2024

Moderators and speakers of the 8th AMR Conference 2024

Aanika Dalal

Co-Director, Alliance for Reducing Microbial Resistance (ARMoR)

Adrian Egli

Director, Institute of Medical Microbiology, University of Zurich

Alan Donnelly

Chair and Founder, The G20&G7 Health and Development Partnership

Alessandra Martini

Policy Officer, European Commission, DG Research and Innovation

Alexander Belcredi

Managing Director, BioNTech R&D (Austria) GmbH

Alexandra Cameron

Senior Expert, Unit Head A.I. Impact Initiatives and Research Coordination, AMR Division, World Health Organization

Baris Ata Borsa

Co-founder and CTO, Theralia AB

Betsy Wonderly Trainor

Alliance Director Diagnostics, CARB-X

Brenda Waning

Chief, STOP TB Global Drug Facility

Cary Adams

CEO, Union for International Cancer Control (UICC)

Caterina Bissantz

Expert Scientist, F. Hoffmann-La Roche

Christoph Dehio

Full Professor of Molecular Microbiology, Director of National Centre of Competence in Research (NCCR) “AntiResist”

Christopher Darlow

NIHR Academic Clinical Lecturer, University of Liverpool

Claudia Zampaloni

Senior Principal Scientist, Antibiotics Discovery, F. Hoffmann-La Roche Ltd

Clive Mason

Programme Director AMR, LifeArc

Coen van Hasselt

Associate Professor, Leiden University

Damiano de Felice

Director of Development and External Engagement, CARB-X

David Paterson

Professor ADVANCE-ID, National University of Singapore

Deepali Patel

Director of international policy, AMR Action Fund

Dennis M. Dixon

Chief of the Bacteriology and Mycology Branch, NIAID, NIH

Dionysios Neofytos

Attending Physician, University Hospital of Geneva

Douglas Häggström

Manager INCATE, University of Basel

Ed Buurman

Alliance Director CARB-X

Florence Séjourné

CEO, Aurobac Therapeutics & Treasurer, BEAM Alliance

Fuad Mirzayev

Team Lead, TB treatment team, World Health Organization

Gail Hayward

Associate Professor, Nuffield Department of Primary Care Health Sciences, University of Oxford

Gemma Johnson

Scientific Director, OLM Diagnostics Ltd

Glenn E. Dale

Chief Development Officer, BioVersys AG

Hee-Jong (Jason) Hwang

CEO, A&J Science

Hoon Sang Lee

Chief Strategy Officer, RIGHT Foundation

Ian Morrissey

Founder & Consultant, Antimicrobial Focus Ltd.

Jean-Baptiste Perrin

Policy Officer, European Commission - DG HERA

Jennifer Cohn

Director, Global Access at Global Antibiotic R&D Partnership (GARDP)

Jennifer Quinn

Global Head of Value and Access, Debiopharm International SA

Jens Hellwage

Managing Director, InfectoGnostics Research Campus Jena

Johan Wikstrom

CEO, Tolka AI Inc.

John J. S. Cadwell

President and CEO, FiberCell Systems Inc.

Jonathan Pearce

CEO, Antibiotic Research UK

Judith Moore

Head of Healthcare Initiatives, World Economic Forum

Kenneth Bradley

Global Head, Infectious Disease Discovery, Roche Pharma Research & Early Development (pRED)

Kevin Outterson

Austin B Fletcher Professor, Boston University, and Executive Director & Principal Investigator, CARB-X

Lara Urban

Principal Investigator, Helmholtz AI

Laura Plant

Head of External Affairs, International Vaccine Institute

Lothar H. Wieler

Chair, Digital Global Public Health, Hasso-Plattner-Institute

Lucas Boeck

Consultant Pulmonary Medicine, University Hospital Basel

Maarten J Postma

Chair, Global Health Economics, University Medical Center Groningen

Magda Rosenmöller

Associate Professor, IESE Business School

Mai Hoang

Senior Scientist, Dynamic42 GmbH

Marc Creus


Marc Gitzinger

CEO, BioVersys AG & President, BEAM Alliance

Marc Lemonnier

CEO, Antabio SAS

Maria Larsson Ortino

Senior Global ESG Manager, Legal & General Investment Management Ltd

Marianne Holm

Senior Research Scientist, Infectious Diseases, Novo Nordisk Foundation

Marie Petit

Partner, Villiger Valuation

Mark Albrecht

Chief, Antimicrobials Branch ASPR/BARDA

Mark Jones

Head of Development, Basilea Pharmaceutica International Ltd | BEAM Alliance - Board Member | Swiss Round Table for Antibiotics - Board Member

Markus Zeitlinger

Professor, Specialist for Internal Medicine and Clinical Pharmacology, Medical University of Vienna

Martin Everett

CSO, Aurobac Therapeutics

Matti Jalasvuori

CEO, PrecisionPhage Ltd.

Maximiliano G. Gutierrez

Principal Group Leader, Francis Crick Institute

Mercedes Gonzalez Moreno

Manager, INCATE

Michael Anderson

CEO, MedAccess

Michele Cecchini

Head of Public Health, Organisation for Economic Co-operation and Development (OECD)

Milovan Stankov-Pugès

CEO, NG Biotech

Mirfin Mpundu

Director, ReAct Africa

Muna Abu Sin

Epidemiologist, Robert Koch Institute

Nelly Badalato

R&D Department manager, GenoScreen

Nicolas Tesse

CSO, Septeos

Nina Khanna

Leading Senior Physician, University Hospital Basel

Olivier Menzel

Senior Health Advisor, Swiss Agency for Development and Cooperation (SDC), Federal Department of Foreign Affairs

Oxana Rucsineanu

Executive Director, Moldova National Association of Tuberculosis Patients

Patricia Martin

COO, LimmaTech Biologics AG

Pierre Dubois

Professor of Economics, Toulouse School of Economics

Pratik Bhatnagar

Global Public Health Director, IQVIA

Radu Botgros

Senior Scientific Officer, European Medicines Agency

Rafael Cantón

Head of Clinical Microbiology Department, Hospital Universitario Ramón y Cajal

Ralf Sudbrak

Interim Secretariat Lead, Global AMR R&D Hub

Ramanan Laxminarayan

President, One Health Trust

Remko van Leeuwen

CEO, SurvivX

Robert Macsics

CEO and Co-founder, smartbax GmbH

Shawna McCallin

Group Leader of Phage Therapy & Research, Balgrist University Hospital

Simon Gottwalt

Project Lead, Swiss antibiotic resistance strategy in human medicine, Swiss Federal Office of Public Health

Sophie Cooper

Senior scientific adviser Science Policy and Research Programme, National Institute for Health and Care Excellence, UK

Soumya Palliyil

CEO & Co-Founder, Brigid Biologics

Stuart Hannah

CEO, Microplate Dx Ltd

Surbhi Malhotra-Kumar

Head, Laboratory of Medical Microbiology, University of Antwerp

Susana Tomásio

Senior Application Scientist, Collaborative Drug Discovery

Thilo Köhler

Senior lecturer, University of Geneva, Department of Microbiology and Molecular Medicine

Thomas Van Boeckel

Assistant Professor, ETH Zurich

Till Bachmann

Deputy Head of Infection Medicine & Personal Chair of Molecular Diagnostics and Infection, University of Edinburgh

Toby Leslie

Global Technical Lead, Fleming Fund / Mott MacDonald

Ulrich Granzer

CEO, Granzer Regulatory Consulting & Services

Ursula Theuretzbacher

Founder, Center for Anti-Infective Agents

Valeria Gigante

Team Lead AMR Division, World Health Organization

Wolfgang Philipp

Acting Deputy Head HERA, European Commission

Yann Ferrisse

Director, Business Development & Partner Engagement, Global Access at Global Antibiotic R&D Partnership (GARDP)

Yves Briers

CEO, Obulytix

Zaki Sellam

CEO, Landmark BioVentures AG

Zoë Molyneux

Policy Lead, Wellcome Trust